Helicobacter pylori infected individual treatment gene chip, preparation method and detection method

Abstract

The invention discloses a gene chip for individualized treatment of Helicobacter pylori infection, a manufacturing method and a detection method. The gene chip includes: wild type and mutation corresponding to clarithromycin resistance mutation sites A2142G and A2143G on the Helicobacter pylori 23s rRNA gene Type SNP typing oligonucleotide probe; wild-type and mutant SNP typing oligonucleotide probes corresponding to quinolone resistance mutation sites N87K, D91G, and D91N on the Helicobacter pylori gyrA gene: human cytochrome Wild-type and mutant SNP typing oligonucleotide probes corresponding to two sites of CYP2C19*2 (G681A) and CYP2C19*3 (G636A) related to proton pump inhibitor metabolism on P450. The gene chip and detection method of the invention can simultaneously detect CYP2C19 gene polymorphism and HP's drug resistance to clarithromycin and quinolone, and has good specificity and sensitivity, good reproducibility and rapid detection.

Description

technical field [0001] The invention relates to a detection technology for Helicobacter pylori, in particular to a gene chip for individualized treatment of Helicobacter pylori infection and a detection method. Background technique [0002] More than half of the world's population is infected with Helicobacter pylori (H. pylori, HP). China is a country with a high H. pylori infection rate, reaching 56.22%, and in some areas as high as 77.22%. Almost all people infected with Helicobacter pylori suffer from chronic gastritis, only a few will develop peptic ulcer, and about 1%-2% of them will develop gastric cancer. Helicobacter pylori infection is closely related to the occurrence and development of clinical gastrointestinal diseases, such as chronic gastritis, peptic ulcer, duodenal ulcer, gastric cancer and lymphocyte hyperplasia. In 1994, WHO classified HP as a class I carcinogen. Studies have shown that Helicobacter pylori infection is the cause of gastric cancer, and th...

AI Technical Summary

Problems solved by technology

Traditional culture and drug susceptibility testing methods have high requirements for laboratories and operators, take a long time (1-2 weeks), have a large workload, and cannot provide information on human CYP2C19 polymorphisms

Rapid detection methods such as PCR have high sensitivity and strong specificity, but the detection throughput is low, and one test can only detect 2-3 targets, which cannot fully meet the actual clinical needs

At present, there is no approved product that can simultaneously detect CYP2C19 gene polymorphism and HP drug resistance. Therefore, it is very necessary to develop products that can simultaneously detect CYP2C19 gene polymorphism and HP drug resistance. Such products have broad applications prospect

Images